SeaStar Medical (ICU) to Release Quarterly Earnings on Wednesday

SeaStar Medical (NASDAQ:ICU) will likely be posting its Q4 2025 results after the market closes on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.97) per share and revenue of $0.2220 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

SeaStar Medical Trading Down 0.9%

Shares of ICU opened at $2.21 on Tuesday. The stock has a market cap of $8.38 million, a P/E ratio of -0.13 and a beta of -1.04. SeaStar Medical has a 1 year low of $2.09 and a 1 year high of $25.70. The stock’s 50-day moving average price is $2.49 and its two-hundred day moving average price is $4.18.

Analyst Ratings Changes

ICU has been the topic of a number of analyst reports. Maxim Group set a $6.00 price target on shares of SeaStar Medical in a research report on Thursday, February 12th. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of SeaStar Medical to a “hold” rating in a research note on Saturday, January 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell” and a consensus target price of $6.00.

Institutional Investors Weigh In On SeaStar Medical

Several large investors have recently modified their holdings of the business. XTX Topco Ltd lifted its holdings in shares of SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after purchasing an additional 48,674 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of SeaStar Medical in the 4th quarter valued at approximately $30,000. Finally, Millennium Management LLC bought a new stake in SeaStar Medical during the 3rd quarter worth approximately $102,000. 1.69% of the stock is currently owned by institutional investors.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.